Clinical trials: Buprenorphine Withdrawal
Substance Withdrawal Syndrome, Opiate Addiction
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
The purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.
- Conditions
- Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
- Trial name
- NCT02801357
- Testing
- lofexidine administration in subjects seeking buprenorphine dose reduction
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Pain, Low Back Pain
Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
The purpose of this study is to determine whether buprenorphine hydrochloride (HCl) buccal film is effective and safe in the treatment of chronic low back pain (CLBP).
- Trial name
- NCT01256450
- Testing
- Buprenorphine
- Where
- 24 sites in United States
- Volunteers
- 334 people
- Sponsor
- BioDelivery Sciences International
Opiate Use Disorder, Opiate Withdrawal Syndrome
An App to Aid in Transitioning Off Opioid Medication
The investigators propose to develop a smartphone app (called BetterOFF) that will help patients manage opioid withdrawal during opioid medication taper and detoxification.
- Trial name
- BetterOFF (NCT03077932)
- Testing
- App Development and Open Pilot
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Butler Hospital
Neonatal Opioid Withdrawal Syndrome
Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)
This randomized control trial will compare buprenorphine and morphine, two currently used medications for the treatment of neonatal opioid withdrawal syndrome (NOWS), in newborns to determine which medication will reduce the…
- Trial name
- NCT04455802
- Where
- United States
- Sponsor
- Women and Infants Hospital of Rhode Island
Opioid-Related Disorders
Pioglitazone to Treat Opioid Withdrawal Symptoms
Background: Opioid-withdrawal symptoms include runny nose, body aches, chills, sweating, and diarrhea. Many people have these symptoms when trying to stop using opioid drugs.
- Trial name
- NCT01517165
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Dependence
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- NCT00447564
- Testing
- Probuphine
- Where
- 18 sites in United States
- Volunteers
- 163 people
- Sponsor
- Titan Pharmaceuticals
Neonatal Abstinence Syndrome
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium.
- Trial name
- NCT00521248
- Testing
- buprenorphine, Oral morphine solution
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Thomas Jefferson University
Opioid Dependence
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- PRO-807 (NCT00630201)
- Testing
- Probuphine (buprenorphine implant)
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Titan Pharmaceuticals
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
The primary objective of this study is to assess lofexidine related effects on QTc (an interval of the heart rhythm) in subjects receiving buprenorphine maintenance.
- Trial name
- NCT01820442
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Opioid Withdrawal, Opioid-use Disorder
Buprenorphine in the Emergency Department
This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal.
- Trial name
- BED (NCT03174067)
- Testing
- Buprenorphine, Clonidine
- Volunteers
- 26 people
- Sponsor
- St. Joseph's Health Centre Toronto
Opioid Use Disorder
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
The goal of this pilot study is to test novel, adjunctive pharmacotherapy for patients with opioid use disorder (POUD) who may be at risk for overdose and other poor opioid use disorder (OUD) outcomes even after initiating…
- Trial name
- DEMURE (NCT07148206)
- Testing
- Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Montefiore Medical Center
Chronic Lower Back Pain, Chronic Pain
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that…
- Trial name
- CAM2038 (NCT02946073)
- Testing
- buprenorphine
- Where
- 69 sites in United States
- Volunteers
- 1,053 people
- Sponsor
- Braeburn Pharmaceuticals
High Dosage Buprenorphine
High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid
The prevalence of analgesics opioids addiction in chronic pain patient is very difficult to know. Many studies indicated that the prevalence of addiction varied from 0% up to 50% in chronic non cancer pain patients, and from 0%…
- Trial name
- SEVROP (NCT03156907)
- Testing
- Buprenorphine
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Clermont-Ferrand
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1).
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs-CMA (NCT03911466)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 12 sites in United States
- Volunteers
- 97 people
- Sponsor
- T. John Winhusen, PhD
Opioid Use Disorder, Opioid Withdrawal
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
There are more than 2.1 million people in the United States with opioid use disorder, and according to preliminary data from the US Centers for Disease Control and Prevention opioid overdose deaths rose 36% to more than 69,000…
- Trial name
- NCT05307458
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- United Health Services Hospitals, Inc.
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032955
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- University of California, Los Angeles
Opioid Abuse, Opioid Dependence
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Buprenorphine is an approved medication for the treatment of opioid dependence. It is typically administered once daily as a sublingual tablet combined with naloxone (i.e., Suboxone).
- Trial name
- NCT01136356
- Testing
- buprenorphine, morphine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Opioid Dependence
Improving Buprenorphine Detoxification Outcomes With Isradipine
This application seeks to address the problem of opioid withdrawal by examining the utility of the L-type calcium channel blocker (CCB) isradipine as an adjunct to BUP detoxification.
- Trial name
- NCT01895270
- Testing
- Isradipine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Arkansas
Opioid Dependency
Re-Treatment Study of Probuphine in Opioid Addiction
Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence.
- Trial name
- NCT01262261
- Testing
- Probuphine (buprenorphine implant)
- Where
- 18 sites in United States
- Volunteers
- 85 people
- Sponsor
- Titan Pharmaceuticals
Opioid Use Disorder, Pregnancy Related
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
The goal of this clinical trial is to compare buprenorphine patch for induction (starting) of buprenorphine in pregnant patients with opioid use disorder. The main questions it aims to answer are: 1.
- Conditions
- Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk, Pregnancy Complications
- Trial name
- Patch BRIDGE (NCT05790252)
- Testing
- Buprenorphine Transdermal Matrix Patch
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine